To Evaluate Efficacy, Safety, Tolerability and PK of Intravenous Cipargamin in Participants With Severe Plasmodium Falciparum Malaria

"Two doses of Intravenous Cipargamin will be evaluated in the initial phase of the study (Cohorts 1-2).~These doses will cover a wider exposure range and facilitate the selection of an appropriate dose for later Cohorts 3-5."

Parenteral artesunate is the WHO recommended first line treatment for severe malaria. Hence IV artesunate is used as comparator. Also, this will be used as rescue medication for participants where IV KAE609 is not working.

Oral Standard of Care